Missed the PR about the name change yesterday, iHub didn't pick it up for whatever reason.
SmooFi Announces Corporate Name Change to NuLife Sciences, Inc. and Stock Symbol Change to "NULF"
SAN CLEMENTE, CA--(Marketwired - December 07, 2016) - SmooFi Inc. (OTCQB: SMFI) today announced that FINRA has approved its corporate name change to NuLife Sciences, Inc. as well as a change of the trading symbol of the Company's common stock. Effective Thursday, December 8th, the Company's shares of common stock will commence trading on the OTC Markets under the trading symbol "NULF" and CUSIP number 67054M105.
The name change was the result of the close of the Asset Purchase Agreement through which NuLife acquired all of the assets of GandTex, LLC, a company with biomedical IP focused on advancing human organ transplant technology and medical research.
"We are moving forward as NuLife Sciences, a name that better reflects our focus on a unique patented proprietary method, the 'NuLife Technique', that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs in human organ transplant," said John Hollister, Chief Executive Officer of NuLife Sciences. "With over 123K candidates waiting for an organ in the U.S. alone, the market need is great with a potential to use discarded or marginal organs. With the Discovery phase completed, we now intend to enter a Preclinical phase involving animal experiments in collaboration with Florida International University and Nova Southeastern University. We look forward to updating investors as our progress moves ahead."
About NuLife Sciences
NuLife Sciences is a biomedical company focused on advancing human organ transplant technology and medical research. NuLife has a patent protected unique proprietary method ("NuLife Technique") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. With a massive need and market for organ transplants, and over 123K candidates waiting for an organ in the U.S. alone, NuLife's versatile technique is suitable for a variety of clinical indications. The Company has completed discovery phase for its technique, and is now entering a Preclinical phase involving animal experiments on its pathway to commercialization. NuLife Sciences will also provide an online marketplace and community to assist in creating jobs and enable entrepreneurs and service providers to offer health related products and services within local markets.
Safe Harbor
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, many of which are beyond the Company's control. The Company's actual results could differ materially and adversely from those anticipated in such forward-looking statements as a result of certain factors, including those set forth below and elsewhere in this press release. All statements, other than statements of historical facts, included in this press release regarding the Company's growth strategy, future operations, financial position, estimated revenue or losses, projected costs, prospects and plans and objectives of management are forward-looking statements. When used in this press release, the words "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," "plan" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements or other information contained herein. Potential investors should not place undue reliance on these forward-looking statements. Although the Company believes that its plans, intentions and expectations reflected in or suggested by the forward-looking statements in this press release are reasonable, the Company cannot assure potential investors that these plans, intentions or expectations will be achieved. The Company discloses important factors that could cause the Company's actual results to differ materially from its expectations under "Risk Factors" and elsewhere in this press release. These cautionary statements qualify all forward-looking statements attributable to the Company or persons acting on its behalf.
Contact Investor Relations Ted Haberfield MZ Group | President - MZ North America Direct: 760-755-2716 Mobile: 858-204-5055 thaberfield@mzgroup.us www.mzgroup.us
